Physician profile
Funchi Tu
NPI 1497927610
$2,048.22
in general payments reported to CMS, 2019-2025
13 companies · $23.25 in 2025
The $23.25 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $471 · 2021: $713 · 2022: $473 · 2023: $155 · 2024: $87.54 · 2025: $23.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,075.83 | 2019-2024 | |
| Amarin Pharma, INC. | $347.97 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $346.20 | 2019-2022 | |
| Amgen INC. | $84.00 | 2019-2020 | |
| Redhill Biopharma INC. | $55.72 | 2022 | |
| Chiesi USA, INC. | $23.25 | 2025 | Kengreal |
| Horizon Therapeutics Plc | $18.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.01 | 2021 | |
| Lilly USA, LLC | $16.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.36 | 2022 | |
| Intra-Sana Laboratories | $14.43 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Funchi Tu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.